XOMA Corp
NASDAQ:XOMA
XOMA Corp
Accounts Receivables
XOMA Corp
Accounts Receivables Peer Comparison
Competitive Accounts Receivables Analysis
Latest Figures & CAGR of Competitors
Company | Accounts Receivables | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
XOMA Corp
NASDAQ:XOMA
|
Accounts Receivables
$3k
|
CAGR 3-Years
-69%
|
CAGR 5-Years
-75%
|
CAGR 10-Years
-52%
|
|
Abbvie Inc
NYSE:ABBV
|
Accounts Receivables
$11.9B
|
CAGR 3-Years
8%
|
CAGR 5-Years
16%
|
CAGR 10-Years
13%
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Accounts Receivables
$4.7B
|
CAGR 3-Years
6%
|
CAGR 5-Years
7%
|
CAGR 10-Years
4%
|
|
Amgen Inc
NASDAQ:AMGN
|
Accounts Receivables
$6.8B
|
CAGR 3-Years
15%
|
CAGR 5-Years
12%
|
CAGR 10-Years
10%
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Accounts Receivables
$1.8B
|
CAGR 3-Years
22%
|
CAGR 5-Years
33%
|
CAGR 10-Years
40%
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Accounts Receivables
$5.2B
|
CAGR 3-Years
8%
|
CAGR 5-Years
18%
|
CAGR 10-Years
17%
|
See Also
What is XOMA Corp's Accounts Receivables?
Accounts Receivables
3k
USD
Based on the financial report for Mar 31, 2024, XOMA Corp's Accounts Receivables amounts to 3k USD.
What is XOMA Corp's Accounts Receivables growth rate?
Accounts Receivables CAGR 10Y
-52%
The average annual Accounts Receivables growth rates for XOMA Corp have been -69% over the past three years , -75% over the past five years , and -52% over the past ten years .